It remains to be seen what share of the costs of weight-loss drugs will be borne by patients or payers
Protein needs vary tremendously depending on age, body size, and physical activity levels
Key information to disclose includes: Medication name and dose "I take Wegovy (semaglutide) 2.4 mg once weekly by subcutaneous injection" Duration of treatment how long you have been taking Wegovy and whether you are still in the dose-escalation phase Current side effects any ongoing nausea, vomiting, diarrhoea, dizziness, or other symptoms Reason for prescription whether prescribed for obesity alone or with comorbidities such as type 2 diabetes, hypertension, or cardiovascular disease Overall health status current weight, blood pressure, and general wellbeing Donation staff will ask about your medical history and may need to consult with medical advisors regarding Wegovy
The relatively lower nausea rate (28% at maximum dose compared to Semaglutides 44%) means fewer people abandon treatment due to side effects
For opened pens, there is an additional in-use expiration period (typically 56 days from the first use), after which the pen should be discarded even if the overall printed expiration date on the pen hasnt passed
